Navigation Links
Atomic structure of the mammalian 'fatty acid factory' determined

Mammalian fatty acid synthase is one of the most complex molecular synthetic machines in human cells. It is also a promising target for the development of anti-cancer and anti-obesity drugs and the treatment of metabolic disorders. Now researchers at ETH Zurich have determined the atomic structure of a mammalian fatty acid synthase. Their results have just been published in Science magazine.

Synthesis of fatty acids is a central cellular process that has been studied for many decades. Fatty acids are used in the cell as energy storage compounds, messenger molecules and building blocks for the cellular envelope. Until now, individual steps of this process have been investigated using isolated bacterial enzymes. However, in higher organisms except plants fatty acid synthesis is catalyzed by large multifunctional proteins where many individual enzymes are brought together to form a "molecular assembly line".

The atomic structure is the result of many years of research

As described in this week's issue of "Science" magazine, researchers at ETH Zurich, supported by the National Centre of Excellence in Research (NCCR) in Structural Biology at the Swiss National Science Foundation, determined the high-resolution structure of a mammalian fatty acid synthase using data collected at the Swiss Light Source (SLS) of the Paul Scherrer Institute (PSI) in Switzerland. These results crown the efforts begun in 2001 to determine the detailed structures of fatty acid synthases in higher organisms by a relatively small group of scientists at ETH Zurich. The group, consisting of Timm Maier, Marc Leibundgut and Simon Jenni in the laboratory of Prof. Nenad Ban, published their first papers describing architectures of fungal and mammalian fatty acid synthases two years ago. That was followed last year by two papers on the atomic structures of fungal fatty acid synthases and the mechanism of substrate shuttling and delivery in these multi-enzymes. Now this latest publication describes the atomic structure of the mammalian fatty acid synthase. These results reveal the details of all catalytic active sites responsible for iterative fatty acid synthesis and show how the flexibility of this large multi-enzyme is used for transferring substrates from one enzymatic active site to the next. The structure can be considered a milestone for future research in the field.

Fatty acid synthases as drug targets?

In addition to the fundamental scientific interest in the function of this multi-enzyme that plays a central role in primary metabolism, mammalian fatty acid synthase is also considered a promising drug target. Although most fat accumulated in animals and humans is delivered to cells by ingestion and not by de novo synthesis, compounds that inhibit the function of the mammalian fatty acid synthase induce weight reduction in animals, showing potential for the treatment of obesity and obesity-related diseases, such as diabetes and coronary disorders. Furthermore, due to the increased requirement for fatty acid synthesis in cancer cells, inhibitors of this enzyme have anti-tumor activity, making fatty acid synthase an attractive drug target for anti-cancer therapy.

Multi-enzymes: the ultimate organic chemists

Mammalian fatty acid synthase belongs to a large family of multi-enzymes, some of which are responsible for the synthesis of complex natural products with antibiotic, anti-cancer, anti-fungal and immunosuppressive properties that are of outstanding medical relevance. The structure of mammalian fatty acid synthase reveals how different catalytic domains are excised or inserted in various members of this family to yield multi-enzymes capable of synthesizing a large variety of chemical products. The structure will facilitate the design of molecular assembly lines for the production of improved compounds. In particular, the engineering of novel multi-enzymes for the production of modified antibiotics is important in the fight against resistant strains of bacteria.


Contact: Professor Nenad Ban
ETH Zurich/Swiss Federal Institute of Technology

Related biology news :

1. Scientists retrace evolution with first atomic structure of an ancient protein
2. Atomic bomb survivor, scientists mark 60 years of long-term radiation study
3. Poxvirus potency uncovered in new atomic map
4. Bikini corals recover from atomic blast
5. New nano-positioners may have atomic-scale precision
6. Researchers discover atomic bomb effect results in adult-onset thyroid cancer
7. Structure of 450 million year old protein reveals evolutions steps
8. A step toward tissue-engineered heart structures for children
9. Scientists learn structure of enzyme in unusual virus
10. Using nanotubes to detect and repair cracks in aircraft wings, other structures
11. Unveiling the structure of microcrystals
Post Your Comments:
(Date:11/19/2015)... YORK , Nov. 19, 2015  Although some ... market is dominated by a few companies, according to ... companies own 51% of the market share of the ... The World Market for Molecular Diagnostic s ... "The market is still controlled by one company ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) Series ... Warrants") subject to the previously disclosed November 1, ... which will result in the issuance of 365,518 ... issuance of such shares, there will be approximately ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading ... culture models, has promoted Melanie Aregger to serve as Chief Operating Officer. ... on the management team and was promoted to Head of InSphero Diagnostics ...
(Date:11/24/2015)... 2015 Capricor Therapeutics, Inc. (NASDAQ: ... discovery, development and commercialization of first-in-class therapeutics, today announced ... is scheduled to present at the 2015 Piper Jaffray ... EST, at The Lotte New York Palace Hotel in ... . --> . ...
(Date:11/24/2015)... and NEW YORK , November 24, ... investment by Bristol-Myers Squibb in a European ... Bristol-Myers Squibb Company in which the companies will work ... immuno-oncology and other areas of unmet medical need. The collaboration ... LSP 5, the latest LSP fund. This is the first ...
Breaking Biology Technology: